{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:52:59Z","timestamp":1767372779764,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"unspecified","delay-in-days":64,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","award":["56078"],"award-info":[{"award-number":["56078"]}],"id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,1,28]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying antirheumatic drugs (bDMARDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients from Rheumatic Diseases Portuguese Register (Reuma.pt) with a clinical diagnosis of axial spondyloarthritis (axSpA) were included. Four subgroups (cross-tabulation between ASDAS (\u22652.1) and BASDAI (\u22654) definitions of high disease activity) were compared regarding baseline characteristics and response to bDMARDs at 3 and 6 months estimated in multivariable regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 594 patients included, the majority (82%) had both BASDAI\u22654\u2009and ASDAS \u22652.1. The frequency of ASDAS \u22652.1, if BASDAI&lt;4 was much larger than the opposite (ie, ASDAS &lt;2.1, if BASDAI\u22654): 62% vs 0.8%. Compared to patients fulfilling both definitions, those with ASDAS \u22652.1\u2009only were more likely to be male (77% vs 51%), human leucocyte antigen B27 positive (79% vs 65%) and have a higher C reactive protein (2.9 (SD 3.5) vs 2.1 (2.9)). Among bDMARD-treated patients (n=359), responses across subgroups were globally overlapping, except for the most \u2018stringent\u2019 outcomes. Patients captured only by ASDAS responded better compared to patients fulfilling both definitions (eg, ASDAS inactive disease at 3 months: 61% vs 25% and at 6 months: 42% vs 25%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The ASDAS definition of high disease activity is more inclusive than the BASDAI definition in selecting patients with axSpA for bDMARD treatment. The additionally \u2018captured\u2019 patients respond better and have higher likelihood of predictors thereof. These results support using ASDAS\u22652.1 as a criterion for treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001145","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T04:35:45Z","timestamp":1583469345000},"page":"e001145","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1595-6497","authenticated-orcid":false,"given":"Jose","family":"Marona","sequence":"first","affiliation":[{"name":"Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisboa, Portugal"},{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-0229","authenticated-orcid":false,"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"},{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"}]},{"given":"Santiago","family":"Rodrigues-Manica","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisboa, Portugal"},{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"given":"Fernando","family":"Pimentel-Santos","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisboa, Portugal"},{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"given":"Ana Filipa","family":"Mour\u00e3o","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisboa, Portugal"},{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"given":"N\u00e9lia","family":"Gouveia","sequence":"additional","affiliation":[{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"given":"Jaime Cunha","family":"Branco","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental EPE, Lisboa, Portugal"},{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"}]},{"given":"Helena","family":"Santos","sequence":"additional","affiliation":[{"name":"Rheumatology, Instituto Portugu\u00eas de Reumatologia, Lisboa, Portugal"}]},{"given":"Elsa","family":"Vieira-Sousa","sequence":"additional","affiliation":[{"name":"Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte EPE, Lisboa, Portugal"},{"name":"Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Filipe","family":"Vinagre","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Garcia de Orta EPE, Almada, Portugal"}]},{"given":"Jo\u00e3o","family":"Tavares-Costa","sequence":"additional","affiliation":[{"name":"Rheumatology, Unidade Local de Saude do Alto Minho EPE, Viana do Castelo, Portugal"}]},{"given":"Jo\u00e3o","family":"Rovisco","sequence":"additional","affiliation":[{"name":"Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal"},{"name":"Cl\u00ednica Universit\u00e1ria de Reumatologia, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal"}]},{"given":"Miguel","family":"Bernardes","sequence":"additional","affiliation":[{"name":"Rheumatology, Centro Hospitalar de Sao Joao EPE, Porto, Portugal"}]},{"given":"Nathalie","family":"Madeira","sequence":"additional","affiliation":[{"name":"Rheumatology, Instituto Portugu\u00eas de Reumatologia, Lisboa, Portugal"}]},{"given":"Rita","family":"Cruz-Machado","sequence":"additional","affiliation":[{"name":"Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte EPE, Lisboa, Portugal"},{"name":"Rheumatology Research Unit, Instituto de Medicina Molecular, Faculty of Medicine, Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Raquel","family":"Roque","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Garcia de Orta EPE, Almada, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-6520","authenticated-orcid":false,"given":"Joana Leite","family":"Silva","sequence":"additional","affiliation":[{"name":"Rheumatology, Unidade Local de Saude do Alto Minho EPE, Viana do Castelo, Portugal"}]},{"given":"Mary Lucy","family":"Marques","sequence":"additional","affiliation":[{"name":"Rheumatology, Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal"}]},{"given":"Raquel Miriam","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Rheumatology, Centro Hospitalar de Sao Joao EPE, Porto, Portugal"}]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[{"name":"CEDOC \u2013 NOVA Medical School | Faculdade de Ci\u00eancias M\u00e9dicas (FCM), Universidade Nova de Lisboa, Lisboa, Portugal"},{"name":"Rheumatology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Rheumatology, Zuyderland Medical Center, Heerlen, Netherlands"}]}],"member":"239","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"2025090313384644000_6.1.e001145.1","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2025090313384644000_6.1.e001145.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.042630"},{"key":"2025090313384644000_6.1.e001145.3","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283470f23"},{"key":"2025090313384644000_6.1.e001145.4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrrheum.2013.93","article-title":"Spondyloarthritis: is it time to replace BASDAI with ASDAS?","volume":"9","author":"Machado","year":"2013","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313384644000_6.1.e001145.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2025090313384644000_6.1.e001145.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100826"},{"key":"2025090313384644000_6.1.e001145.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016386"},{"key":"2025090313384644000_6.1.e001145.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124446"},{"key":"2025090313384644000_6.1.e001145.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep422"},{"key":"2025090313384644000_6.1.e001145.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.081048"},{"key":"2025090313384644000_6.1.e001145.11","doi-asserted-by":"publisher","DOI":"10.1186\/ar3369"},{"key":"2025090313384644000_6.1.e001145.12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.reuma.2013.12.006","article-title":"ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy","volume":"10","author":"Vastesaeger","year":"2014","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"2025090313384644000_6.1.e001145.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.138594"},{"key":"2025090313384644000_6.1.e001145.14","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Assessment of Spondyloarthritis International Society (ASAS) Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090313384644000_6.1.e001145.15","first-page":"752","article-title":"Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis","volume":"28","author":"Aydin","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313384644000_6.1.e001145.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes142"},{"key":"2025090313384644000_6.1.e001145.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker087"},{"key":"2025090313384644000_6.1.e001145.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2734-8"},{"key":"2025090313384644000_6.1.e001145.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes057"},{"key":"2025090313384644000_6.1.e001145.20","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025090313384644000_6.1.e001145.21","first-page":"45","article-title":"Reuma.pt\u2014the rheumatic diseases Portuguese register","volume":"36","author":"Canh\u00e3o","year":"2011","journal-title":"Acta Reumatol Port"},{"key":"2025090313384644000_6.1.e001145.22","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-015-0522-3","article-title":"Clinical tools to assess and monitor spondyloarthritis","volume":"17","author":"Landew\u00e9","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313384644000_6.1.e001145.23","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2025090313384644000_6.1.e001145.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"2025090313384644000_6.1.e001145.25","first-page":"15","article-title":"Portuguese recommendations for the use of biological therapies in patients with axial spondyloarthritis \u2013 December 2011 update","volume":"37","author":"Machado","year":"2012","journal-title":"Acta Reumatol Port"},{"key":"2025090313384644000_6.1.e001145.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"2025090313384644000_6.1.e001145.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.23606"},{"key":"2025090313384644000_6.1.e001145.28","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139667"},{"key":"2025090313384644000_6.1.e001145.29","doi-asserted-by":"publisher","DOI":"10.1002\/art.24408"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:38:53Z","timestamp":1756931933000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,3,5]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/rmdopen-2019-001145"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001145","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}